These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics. Loew GH; Berkowitz DS J Med Chem; 1978 Jan; 21(1):101-6. PubMed ID: 73588 [TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues. Sayre LM; Larson DL; Takemori AE; Portoghese PS J Med Chem; 1984 Oct; 27(10):1325-35. PubMed ID: 6090663 [TBL] [Abstract][Full Text] [Related]
27. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329 [TBL] [Abstract][Full Text] [Related]
28. Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids. Spetea M; Nevin ST; Hosztafi S; Rónai AZ; Tóth G; Borsodi A Neurochem Res; 1998 Sep; 23(9):1211-6. PubMed ID: 9712193 [TBL] [Abstract][Full Text] [Related]
29. Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels. Sayre LM; Larson DL; Fries DS; Takemori AE; Portoghese PS J Med Chem; 1983 Sep; 26(9):1229-35. PubMed ID: 6310111 [TBL] [Abstract][Full Text] [Related]
30. Effects of oxymorphazone in frogs: long lasting antinociception in vivo, and apparently irreversible binding in vitro. Benyhe S; Hoffmann G; Varga E; Hosztafi S; Toth G; Borsodi A; Wollemann M Life Sci; 1989; 44(24):1847-57. PubMed ID: 2472540 [TBL] [Abstract][Full Text] [Related]
32. Irreversible opiate agonists and antagonists. IV. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. Williams CL; Bodnar RJ; Clark JE; Hahn EF; Burks TF; Pasternak GW J Pharmacol Exp Ther; 1988 Apr; 245(1):8-12. PubMed ID: 2452249 [TBL] [Abstract][Full Text] [Related]
33. Investigation of phenolic bioisosterism in opiates: 3-sulfonamido analogues of naltrexone and oxymorphone. McCurdy CR; Jones RM; Portoghese PS Org Lett; 2000 Mar; 2(6):819-21. PubMed ID: 10754685 [TBL] [Abstract][Full Text] [Related]
34. Potential affinity labels for the opiate receptor based on fentanyl and related compounds. Maryanoff BE; Simon EJ; Gioannini T; Gorissen H J Med Chem; 1982 Aug; 25(8):913-9. PubMed ID: 6288945 [TBL] [Abstract][Full Text] [Related]
35. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes. Tam SW; Liu-Chen LY J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954 [TBL] [Abstract][Full Text] [Related]
36. Effects of N-methylnaloxone and N-methylnaltrexone on nociception and precipitated abstinence in mice. Ramabadran K Life Sci; 1982 Sep 20-27; 31(12-13):1253-6. PubMed ID: 6183549 [TBL] [Abstract][Full Text] [Related]
37. 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors. Ohkawa S; DiGiacomo B; Larson DL; Takemori AE; Portoghese PS J Med Chem; 1997 May; 40(11):1720-5. PubMed ID: 9171881 [TBL] [Abstract][Full Text] [Related]
38. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Hermens JM; Ebertz JM; Hanifin JM; Hirshman CA Anesthesiology; 1985 Feb; 62(2):124-9. PubMed ID: 2578752 [TBL] [Abstract][Full Text] [Related]
39. A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site. Rothman RB; Bowen WD; Herkenham M; Jacobson AE; Rice KC; Pert CB Mol Pharmacol; 1985 Mar; 27(3):399-409. PubMed ID: 2579319 [TBL] [Abstract][Full Text] [Related]
40. Irreversible and reversible narcotic agonists: discriminative and analgesic effects of buprenorphine, oxymorphazone, and morphine. France CP; Jacobson AE; Woods JH NIDA Res Monogr; 1984 Mar; 49():136-42. PubMed ID: 6207431 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]